On December 14, 2021 Algok Bio Inc., a biopharmaceutical start-up based in Bellevue, Washington, developing next-generation therapeutics for unmet medical needs, reported a license agreement with Korea Atomic Energy Research Institute (KAERI) to obtain exclusive global rights of antibody technology targeting transmembrane 4 L six family member 4 (TM4SF4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TM4SF4 has been known to be a novel cell surface marker preferentially expressed in cancer stem cells and involved in the growth and metastasis of lung cancer. To inhibit the tumor-promoting effect of TM4SF4, KAERI successfully designed a mouse monoclonal antibody and manufactured a humanized antibody, maintaining its affinity but reducing immune rejection in the human body. KAERI also confirmed that it acts as a radio-sensitizer, preventing lung cancer cells from resistant to radiation therapy.

Algok Bio and KAERI will also have a research collaboration to support Algok Bio’s future development activities for 3 years, which are planned to be conducted in the US and South Korea.

(Press release, Algok Bio, DEC 14, 2021, View Source [SID1234662152])

On December 14, 2021 Aucentra reported that it is excited to be awarded a seed-start grant of $700k by the South Australian government’s research and innovation fund (Press release, Aucentra, DEC 14, 2021, View Source [SID1234606756]). This funding will be used to test Aucentra’s leading drug candidate Auceliciclib.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Auceliciclib, if successful in its clinical trials, will be a game-changing treatment of glioblastoma multiforme, which is the most aggressive type of brain cancer and the most difficult to treat.

The Minister for Innovation and Skills David Pisoni recognised Aucentra’s ground-breaking achievements; "I am incredibly proud of Professor Wang and her team at the University of South Australia for the amazing work they have accomplished".

Auceliciclib is a CDK4 and 6 inhibitor with a high specificity which allows for prevention of cancer cell growth and proliferation with fewer side effects. Read the full article here: View Source

On December 14, 2021 Aucentra reported that it is excited to be awarded a seed-start grant of $700k by the South Australian government’s research and innovation fund (Press release, Aucentra, DEC 14, 2021, View Source [SID1234598161]). This funding will be used to test Aucentra’s leading drug candidate Auceliciclib.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Auceliciclib, if successful in its clinical trials, will be a game-changing treatment of glioblastoma multiforme, which is the most aggressive type of brain cancer and the most difficult to treat.

The Minister for Innovation and Skills David Pisoni recognised Aucentra’s ground-breaking achievements; "I am incredibly proud of Professor Wang and her team at the University of South Australia for the amazing work they have accomplished".

Auceliciclib is a CDK4 and 6 inhibitor with a high specificity which allows for prevention of cancer cell growth and proliferation with fewer side effects. Read the full article here: View Source

On December 14, 2021 Carterra, Inc. the world leader in label-free high throughput antibody screening and characterization, reported that it has signed an exclusive Asia-Pacific and Oceania region distribution agreement with PerkinElmer, Inc. a global leader committed to innovating for a healthier world (Press release, PerkinElmer, DEC 14, 2021, View Source [SID1234597443]). With the agreement, PerkinElmer will market, sell, and service Carterra’s flagship LSA high-throughput surface plasmon resonance (SPR) platform and software used for accelerating the discovery of therapeutic antibodies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This move will assist Carterra in meeting growing customer demand by leveraging PerkinElmer’s long-standing channel infrastructure in the region. It will also add additional tools to PerkinElmer’s growing portfolio of science and biologics discovery offerings, which includes its world leading BioLegend antibody and reagent technologies.

This new agreement builds on the equity investment PerkinElmer made in Carterra last December, which has resulted in several collaborations between the companies involving assay development and software integration projects over the past year.

Commenting on this latest distribution arrangement, Alan Fletcher, Senior Vice President, Life Science, PerkinElmer, said, "We are delighted to add the distribution of Carterra’s highly innovative LSA technology to help our Asia-Pacific and Oceania customers further streamline and advance their biologic and biotherapeutic discovery and development work."

"Carterra recognized early on that Asia-Pacific and Oceania would be important markets for our game changing biologics discovery products and we are at the point where we need additional reach and channel power to help us take our customer delivery there to the next level, " stated Tim Germann, Chief Commercial Officer at Carterra. "We are excited to collaborate with PerkinElmer to add that extra horsepower in sales, marketing and service as well as benefit from their deep life science expertise across drug development workflows."

On December 14, 2021 PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer reported that it has been invited to present at the DNB Nordic Healthcare Conference 2021, an Oslo based online event hosted by DNB (Press release, PCI Biotech, DEC 14, 2021, View Source [SID1234597416]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On Thursday, 16 December 2021 at 11:10 (CET), Dr. Per Walday, CEO, will present an overview of PCI Biotech’s proprietary platform technology via a general company presentation. The Company is also available for 1:1 meetings with potential partners and investors.

The presentation slides will be made available on PCI Biotech’s website (www.pcibiotech.com) under "Other presentations".